Date: 2015-04-24
Type of information: Product acquisition
Compound: coltuximab ravtansine (formerly SAR3419)
Company: Immunogen (USA - MA) Sanofi (France)
Therapeutic area: Cancer - Oncology
Type agreement: product acquisition
Action mechanism: antibody drug conjugate. Coltuximab ravtansine (formerly SAR3419) is a CD19-targeting ADC created by ImmunoGen to treat diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies.
Disease: diffuse large B-cell lymphoma and other B-cell malignancies
Details: * On April 24, 2015, Immunogen reported third quarter fiscal year 2015 financial results and provided an update of its product pipeline. The company announced that it has recently regained rights to coltuximab ravtansine (SAR3419) from Sanofi. This potential therapy for diffuse large B-cell lymphoma and other B-cell malignancies demonstrated encouraging activity in the treatment of relapsed/refractory diffuse large B-cell lymphoma in STARLYTE Phase 2 trial presented at ASCO 2014.
Financial terms:
Latest news: * On March 4, 2016, in its annual report, Sanofi has announced that the coltuximab ravtansine (SAR3419) program has been discontinued in Phase II and the rights returned to Immunogen.
